|
[1]
|
Tomasini, P., Barlesi, F., Mascaux, C., et al. (2016) Pemetrexed for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: Latest Evidence about Its Extended Use and Outcomes. Therapeutic Advances in Medical Oncology, 8, 198-208. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Liu, D., Wu, J., Shi, G.Y. (2014) Role of XRCC1 and ERCC5 Polymorphisms on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. Genetics and Molecular Research, 13, 3100-3107. [Google Scholar] [CrossRef]
|
|
[3]
|
Yaman, B., Nart, D., Ekren, P.K., et al. (2015) Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis. Turkish Journal of Pathology, 31, 163-174. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Dong, H., Bao, D., Guo, X., et al. (2015) Effect of Thymidylate Synthase Gene Polymorphism on the Response to Chemotherapy and Clinical Outcome of Non-Small Cell Lung Cancer Patients. Tumor Biology, 36, 7151-7157. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Sun, J.M., Ahn, J.S., Jung, S.H., et al. (2015) Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Bio-marker-Stratified Randomized Phase II Trial. Journal of Clinical Oncology, 33, 2450-2456. [Google Scholar] [CrossRef]
|
|
[6]
|
李燕, 杨明珍. 弥漫大B细胞淋巴瘤免疫组化标记的预后意义及利妥昔单抗对其影响临床研究[J]. 中国实用内科杂志, 2014, 34(2): 187-190.
|
|
[7]
|
Tian, D., Pei, Y., Zheng, Q., et al. (2017) Effect of Vis-ceral Pleural Invasion on the Prognosis of Patients with Lymph Node Negative Non-Small Cell Lung Cancer. Thoracic Cancer, 8, 97-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Elsamany, S.A., Al-Fayea, T.M., Alzahrani, A.S., et al. (2015) Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome. Asian Pacific Organization for Cancer Prevetion, 16, 2987-2991. [Google Scholar] [CrossRef]
|
|
[9]
|
El-Maqsoud, N.M., Tawfiek, E.R., Abdelmeged, A., et al. (2016) The Diagnostic Utility of the Triple Markers Napsin A, TTF-1, and PAX8 in Differentiating between Primary and Metastatic Lung Carcinomas. Tumor Biology, 37, 3123-3134. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Winslow, M.M., Dayton, T.L., Verhaak, R.G., et al. (2013) Suppression of Lung Adenocarcinoma Progression by Nkx2-1. Nature, 473, 101-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lee, J.S., Kim, H.R., Lee, C.Y., et al. (2013) EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases. Annals of Surgical Oncology, 20, 3015-3022. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Liu, Q., Yu, Z., Xiang, Y., Wu, N., et al. (2015) Prognostic and Predictive Significance of Thymidylate Synthase Protein Expression in Non-Small Celllung Cancer: A Systematic Review and Me-ta-Analysis. Cancer Biomarkers, 15, 65-78. [Google Scholar] [CrossRef]
|
|
[13]
|
Yang, M., Fan, W.F., Pu, X.L., et al. (2017) The Role of Thymidylate Synthase in Non-Small Cell Lung Cancer Treated with Pemetrexed Continuation Maintenance Therapy. Journal of Chemotherapy, 29, 106-112. [Google Scholar] [CrossRef]
|
|
[14]
|
Giovannetti, E., Zucali, P.A., Rolfo, C., et al. (2016) Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. Journal of Clinical Oncology, 34, 511-512. [Google Scholar] [CrossRef]
|